Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383671670> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4383671670 endingPage "69" @default.
- W4383671670 startingPage "64" @default.
- W4383671670 abstract "Introduction: Infections from gram negative bacilli is a challenge for clinicians and laboratory personnel. Treatment of these infections remained as an area of concern. Both fluroquinolones and cephalosporins are most common choice of antibiotics. Despite Cephalosporins, being drug of choice they are expensive also showed many adverse reactions. This study, compares and reevaluates the susceptibility of gram negative bacteria to fluroquinolones (ciprofloxacin) compared to cephalosporins. Method: Various samples(pus, sputum, urine, blood and bodyfluids) were processed according to standard protocols. Antibiotic done susceptibility by using Kirby-baur disc diffusion method. ESBL and Amp C producers were identified using CLSI guidelines. Result: Among 400 isolates, majority were from pus followed by urine, sputum. The most common organism isolated was Klebsiella spp, (33.25%) Escherichia coli (29.5%), Pseudomonas spp (27.25%), Enterobacter spp (6.25%), Citrobacter 5 (1.25%), and Acinetobacter spp (2.5%). Isolates showed 20-80% susceptibility to ciprofloxacin, 30-60% to third and fourth generation cephalosporins. Klebsiella and Pseudomonas showed 64% and 31% susceptibility to ciprofloxacin. Acinetobacter spp showed 30% susceptibility to cefipime and 20% to ciprofloxacin. 34 isolates were ESBL 18 were AmpC producers, of which 15(44%) ESBL and 7(38%) of AmpC producers were ciprofloxacin susceptible. Conclusion: Ciprofloxacin was found to be more effective than the fourth generation cephalosporin (cefepime) against gram negative bacilli. Ciprofloxacin can be considered for treatment as it is more active and cost effective when compared to cephalosporins. Keywords: Fluroquinolones, Cephalosporins, Multidrug resistant, ESBL, Amp C" @default.
- W4383671670 created "2023-07-09" @default.
- W4383671670 creator A5084056925 @default.
- W4383671670 date "2023-07-08" @default.
- W4383671670 modified "2023-09-30" @default.
- W4383671670 title "Comparison of in-vitro Antibiotic Susceptibility of Ciprofloxacin, Cefotaxime, Ceftazidime and Cefepime against Gram Negative Bacilli Infections - A Study from Tertiary Care Centre" @default.
- W4383671670 doi "https://doi.org/10.46347/jmsh.v9i1.22.369" @default.
- W4383671670 hasPublicationYear "2023" @default.
- W4383671670 type Work @default.
- W4383671670 citedByCount "0" @default.
- W4383671670 crossrefType "journal-article" @default.
- W4383671670 hasAuthorship W4383671670A5084056925 @default.
- W4383671670 hasBestOaLocation W43836716701 @default.
- W4383671670 hasConcept C104317684 @default.
- W4383671670 hasConcept C142724271 @default.
- W4383671670 hasConcept C2776301714 @default.
- W4383671670 hasConcept C2776968632 @default.
- W4383671670 hasConcept C2777050379 @default.
- W4383671670 hasConcept C2777637488 @default.
- W4383671670 hasConcept C2778512257 @default.
- W4383671670 hasConcept C2778523567 @default.
- W4383671670 hasConcept C2778719061 @default.
- W4383671670 hasConcept C2778983983 @default.
- W4383671670 hasConcept C2779116282 @default.
- W4383671670 hasConcept C2779631663 @default.
- W4383671670 hasConcept C2781069245 @default.
- W4383671670 hasConcept C501593827 @default.
- W4383671670 hasConcept C523546767 @default.
- W4383671670 hasConcept C54355233 @default.
- W4383671670 hasConcept C547475151 @default.
- W4383671670 hasConcept C55493867 @default.
- W4383671670 hasConcept C64778159 @default.
- W4383671670 hasConcept C71924100 @default.
- W4383671670 hasConcept C86803240 @default.
- W4383671670 hasConcept C89423630 @default.
- W4383671670 hasConcept C94665300 @default.
- W4383671670 hasConceptScore W4383671670C104317684 @default.
- W4383671670 hasConceptScore W4383671670C142724271 @default.
- W4383671670 hasConceptScore W4383671670C2776301714 @default.
- W4383671670 hasConceptScore W4383671670C2776968632 @default.
- W4383671670 hasConceptScore W4383671670C2777050379 @default.
- W4383671670 hasConceptScore W4383671670C2777637488 @default.
- W4383671670 hasConceptScore W4383671670C2778512257 @default.
- W4383671670 hasConceptScore W4383671670C2778523567 @default.
- W4383671670 hasConceptScore W4383671670C2778719061 @default.
- W4383671670 hasConceptScore W4383671670C2778983983 @default.
- W4383671670 hasConceptScore W4383671670C2779116282 @default.
- W4383671670 hasConceptScore W4383671670C2779631663 @default.
- W4383671670 hasConceptScore W4383671670C2781069245 @default.
- W4383671670 hasConceptScore W4383671670C501593827 @default.
- W4383671670 hasConceptScore W4383671670C523546767 @default.
- W4383671670 hasConceptScore W4383671670C54355233 @default.
- W4383671670 hasConceptScore W4383671670C547475151 @default.
- W4383671670 hasConceptScore W4383671670C55493867 @default.
- W4383671670 hasConceptScore W4383671670C64778159 @default.
- W4383671670 hasConceptScore W4383671670C71924100 @default.
- W4383671670 hasConceptScore W4383671670C86803240 @default.
- W4383671670 hasConceptScore W4383671670C89423630 @default.
- W4383671670 hasConceptScore W4383671670C94665300 @default.
- W4383671670 hasIssue "1" @default.
- W4383671670 hasLocation W43836716701 @default.
- W4383671670 hasOpenAccess W4383671670 @default.
- W4383671670 hasPrimaryLocation W43836716701 @default.
- W4383671670 hasRelatedWork W1985172487 @default.
- W4383671670 hasRelatedWork W1988998857 @default.
- W4383671670 hasRelatedWork W2036297853 @default.
- W4383671670 hasRelatedWork W2111785754 @default.
- W4383671670 hasRelatedWork W2145679126 @default.
- W4383671670 hasRelatedWork W2290561783 @default.
- W4383671670 hasRelatedWork W2414259271 @default.
- W4383671670 hasRelatedWork W2460047944 @default.
- W4383671670 hasRelatedWork W3175563318 @default.
- W4383671670 hasRelatedWork W4221036093 @default.
- W4383671670 hasVolume "9" @default.
- W4383671670 isParatext "false" @default.
- W4383671670 isRetracted "false" @default.
- W4383671670 workType "article" @default.